Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 630

1.

Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases.

Federici AB, Sacco R, Stabile F, Carpenedo M, Zingaro E, Mannucci PM.

Haemophilia. 2000 Mar;6(2):71-7.

PMID:
10781191
2.

Haemostatic management of intraoral bleeding in patients with von Willebrand disease.

Morimoto Y, Yoshioka A, Sugimoto M, Imai Y, Kirita T.

Oral Dis. 2005 Jul;11(4):243-8.

PMID:
15984956
3.

Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.

Federici AB, Baudo F, Caracciolo C, Mancuso G, Mazzucconi MG, Musso R, Schinco PC, Targhetta R, Mannuccio Mannucci P.

Haemophilia. 2002 Nov;8(6):761-7.

PMID:
12410644
4.

Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.

Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.

Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. Review.

PMID:
17164493
5.

Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.

Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G.

Haematologica. 2003 Nov;88(11):1279-83.

7.

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.

Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, Retzios AD, Kapelan BA, Schwartz RS, Kessler C; Alphanate Study Group.

Blood. 2002 Jan 15;99(2):450-6.

8.

Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients.

Federici AB, Castaman G, Franchini M, Morfini M, Zanon E, Coppola A, Tagliaferri A, Boeri E, Mazzucconi MG, Rossetti G, Mannucci PM.

Haematologica. 2007 Jul;92(7):944-51.

9.

Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.

Michiels JJ, van Vliet HH, Berneman Z, Schroyens W, Gadisseur A.

Acta Haematol. 2009;121(2-3):167-76. doi: 10.1159/000214857. Epub 2009 Jun 8. Review.

PMID:
19506363
10.
11.

Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).

Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.

Blood Coagul Fibrinolysis. 2004 Jun;15(4):323-30.

PMID:
15166918
12.

Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.

Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM.

J Thromb Haemost. 2007 Jun;5(6):1115-24.

PMID:
17403090
13.

Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.

Hernandez-Navarro F, Quintana M, Jimenez-Yuste V, Alvarez MT, Fernandez-Morata R.

Haemophilia. 2008 Sep;14(5):963-7. doi: 10.1111/j.1365-2516.2008.01784.x. Epub 2008 Jul 9.

PMID:
18624696
14.

Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.

Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z.

Semin Thromb Hemost. 2006 Sep;32(6):636-45. Review.

PMID:
16977574
15.

Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.

Dunkley S, Baker RI, Pidcock M, Price J, Seldon M, Smith M, Street A, Maher D, Barrese G, Stone C, Lloyd J.

Haemophilia. 2010 Jul 1;16(4):615-24. doi: 10.1111/j.1365-2516.2010.02206.x. Epub 2010 Mar 16.

PMID:
20331755
16.

von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.

Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM; HAEMATE P Surgical Study Group.

J Thromb Haemost. 2007 Jul;5(7):1420-30. Epub 2007 Apr 16.

PMID:
17439628
17.

Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history.

Sánchez-Luceros A, Meschengieser SS, Woods AI, Chuit R, Turdó K, Blanco A, Lazzari MA.

Thromb Haemost. 2010 Nov;104(5):984-9. doi: 10.1160/TH10-04-0220. Epub 2010 Sep 30.

PMID:
20886181
18.

Management options for dental extraction in hemophiliacs: a study of 55 extractions (2000-2002).

Frachon X, Pommereuil M, Berthier AM, Lejeune S, Hourdin-Eude S, Quéro J, Mézière X, De Mello G, Garnier J.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):270-5.

PMID:
15716831
19.

Hyper-responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra-platelet von Willebrand factor.

Rodeghiero F, Castaman G, Di Bona E, Ruggeri M, Lombardi R, Mannucci PM.

Eur J Haematol. 1988 Feb;40(2):163-7.

PMID:
3126081
20.

The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).

Federici AB.

Haemophilia. 2008 Jan;14 Suppl 1:5-14. doi: 10.1111/j.1365-2516.2007.01610.x. Review.

PMID:
18173689
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk